Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update Portfolio News / By Karina Tin November 14, 2022 Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update Read More »
Nurix Announces DeTIL-0255 Scientific Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) and Successful Completion of DeTIL-0255 Phase 1 Safety Run-in Portfolio News / By Karina Tin November 10, 2022 Nurix Announces DeTIL-0255 Scientific Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) and Successful Completion of DeTIL-0255 Phase 1 Safety Run-in Read More »
RAPT Therapeutics Reports Third Quarter 2022 Financial Results Portfolio News / By Karina Tin November 10, 2022 RAPT Therapeutics Reports Third Quarter 2022 Financial Results Read More »
Tenaya Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update Portfolio News / By Karina Tin November 10, 2022 Tenaya Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update Read More »
Nurix Announces Initial NX-1607 Phase 1 Data Presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Demonstrating Targeted CBL-B Inhibition in Patients with Advanced Malignancies Portfolio News / By Karina Tin November 10, 2022 Nurix Announces Initial NX-1607 Phase 1 Data Presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Demonstrating Targeted CBL-B Inhibition in Patients with Advanced Malignancies Read More »
eFFECTOR Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update Portfolio News / By Karina Tin November 7, 2022 eFFECTOR Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update Read More »
ORIC Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Update Portfolio News / By Karina Tin November 7, 2022 ORIC Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Update Read More »
Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress Portfolio News / By Karina Tin November 7, 2022 Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress Read More »
A2 Bio Identifying Solid Tumor Patients for Possible Inclusion in Phase 1 Studies Targeting CEA and Mesothelin Expected to Begin in 2023: Update at SITC 2022 Portfolio News / By Karina Tin November 7, 2022 A2 Bio Identifying Solid Tumor Patients for Possible Inclusion in Phase 1 Studies Targeting CEA and Mesothelin Expected to Begin in 2023: Update at SITC 2022 Read More »
NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results Portfolio News / By Karina Tin November 3, 2022 NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results Read More »
